A biotech choosing a CDMO is not buying a service. They are deciding who to trust with the physical existence of their drug. That changes everything about how they search, how long it takes, and what gets you considered.
The search starts earlier than you think
By the time a biotech issues a formal request for proposal, they have usually been quietly forming opinions for months. They have searched for CDMOs with their modality. They have browsed directories to see who exists at their scale. They have asked people they trust. They have built a mental map of the market long before anyone at your company knows they exist.
This is why CDMO marketing cannot be reactive. If you only become visible when an RFP is circulating, you are arriving after the consideration set has already formed in the buyer’s head.
What they are filtering for
A biotech scanning CDMOs is asking a narrow set of questions, and most of them are about fit rather than excellence.
- Modality. Small molecule, biologic, cell and gene, ADC, sterile injectable. This is the first filter and it is brutal. A cell therapy company will not spend three seconds on a CDMO that does not clearly do cell therapy.
- Scale. Can you make what they need at the volume they need, now and after they grow? A CDMO that cannot carry them to commercial supply creates a future technology transfer, and they know it.
- Capacity. Do you actually have a slot? In a constrained market this is a real question, not a formality.
- Quality record. A compliance problem at your site becomes their compliance problem. This is the single highest-stakes item on the list.
- Whether they will matter to you. Small biotechs are genuinely afraid of being the smallest client at a giant. It is a live fear and worth addressing directly.
Trust is the product
Everything in CDMO selection reduces to one thing: will this partner deliver on time, to standard, without putting the program at risk?
That is why proof beats promise so decisively here. Specific capabilities, real modality experience, quality track record, facility detail, and the ability to describe how a technology transfer would actually work are worth more than any amount of language about excellence and partnership. Every CDMO says they are a trusted partner. Almost none of them show it.
The specialist advantage nobody uses
If you are a mid-sized or specialist CDMO competing against the giants, your advantage is not capacity. It is attention.
The biotech you want is worried about being ignored at a large partner, and you can credibly promise senior engagement and flexibility that a giant cannot. But this only works if the biotech can find you and immediately understand what you specialize in. Specialists lose to giants not because they are worse but because they are invisible at the moment of search, and a biotech cannot choose a company it never saw.
Where the search actually happens
Biotechs find manufacturing partners through referrals, conferences, search, and category directories, and directories carry a specific weight in this category because the buyer is often trying to discover options rather than validate ones they already know.
A biotech browsing a CDMO directory is asking: who can make my molecule? If your entry does not answer that in five seconds, the answer is not you. And when buyers write to us directly asking for a manufacturing partner, and they do, including a top-five global pharma recently, the companies we can put forward are the ones whose capabilities we have on file.
Be the company they find
Biotechs are searching for manufacturing partners right now, and some of them are asking us directly. Make sure there is something to find when they look.
Get a featured listing and dedicated landing page, $5,000/year
Or start with a featured profile, $3,000/year
Both carry a 90-day guarantee: if your listing does not generate measurable referral traffic, we extend it by a quarter at no cost. Browse the CDMO directory to see exactly where your company would sit, and read how biotech buyers actually choose vendors for the wider picture.
Frequently asked questions
How do biotechs choose a CDMO?
Biotechs form opinions long before an RFP circulates, searching for CDMOs with their modality, browsing directories to see who exists at their scale, and asking trusted contacts. They filter on modality first, then scale, real available capacity, quality and compliance record, and whether they will actually matter as a client. Underneath it all, the decision is about trust.
What do biotechs look for in a CDMO?
Modality fit is the first and harshest filter, since a cell therapy company will skip any CDMO that does not clearly do cell therapy. After that: scale that carries them to commercial supply, genuinely available capacity, a clean quality and regulatory track record, and reassurance that a smaller client will still receive senior attention.
How can a specialist CDMO compete with the giants?
On attention rather than capacity. Biotechs fear being the smallest client at a large partner, so a specialist can credibly offer senior engagement and flexibility. But this only works if the biotech can find you and instantly understand your specialization. Specialists usually lose to giants because they are invisible at the moment of search, not because they are worse.
